BriaCell Therapeutics Announces Closing of US$30 million Public Offering

Core Viewpoint - BriaCell Therapeutics Corp. has successfully closed a public offering of 5,366,726 units, raising approximately US$30 million to support its business objectives and working capital needs [1][2]. Group 1: Offering Details - Each unit in the offering consists of one common share (or one pre-funded warrant) and one warrant, sold at a price of US$5.59 per unit [1]. - The warrants are immediately exercisable at an exercise price of US$6.93 per share and will expire five years from the date of issuance [1]. - The warrants have been approved for listing on the Nasdaq Capital Market under the symbol "BCTXL" and began trading on January 14, 2026 [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital requirements, general corporate purposes, and advancing the company's business objectives [2]. Group 3: Regulatory Information - A registration statement related to the securities was filed with the SEC on December 23, 2025, and became effective on January 13, 2026 [3]. - The offering was conducted in accordance with the exemption set forth in Section 602.1 of the TSX Company Manual [2]. Group 4: Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [5].